Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting [Yahoo! Finance]
Ocuphire Pharma, Inc. (OCUP)
Company Research
Source: Yahoo! Finance
company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that Daniel Su, M.D. will deliver a paper presentation on oral APX3330 at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 5-9, 2024 in Seattle, Washington. Key details about Dr. Su's presentation at the ARVO 2024 Annual Meeting are below: Title of Presentation: Oral APX3330, a Ref-1 Inhibitor, Slows Progression of Diabetic Retinopathy on a Binocular DRSS Person-Level Scale Presenter: Daniel Su, M.D., Retina Vitreous Associates Medical Group Presentation Number: Paper Session: Diabetic Retinopathy Date: Sunday, May 5, 2024 Time: 4:00 – 4:15 pm PT Location: Arch Building, 6E, Seattle Convention Center About Ocuphire Pharma Ocuphire is a clinical-stage ophthalmic biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders. Ocuphi
Show less
Read more
Impact Snapshot
Event Time:
OCUP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUP alerts
High impacting Ocuphire Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
OCUP
News
- Ocuphire Pharma to Present at the Aegis Virtual ConferenceGlobeNewswire
- Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual MeetingGlobeNewswire
- First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery [Yahoo! Finance]Yahoo! Finance
- First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive SurgeryGlobeNewswire
- Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner ViatrisGlobeNewswire
OCUP
Earnings
- 11/13/23 - Beat
OCUP
Sec Filings
- 4/29/24 - Form ARS
- 4/29/24 - Form DEFA14A
- 4/29/24 - Form DEF
- OCUP's page on the SEC website